At the heart of this investigation are the patient-specific cerebral organoids—tiny, self-organizing clusters of brain tissue generated in vitro from patients’ skin or blood cells reprogrammed to induced pluripotent stem cells. These “mini-brains” faithfully recapitulate critical cellular and molecular hallmarks of the disease, allowing researchers unparalleled access to observe neurodegenerative progression on a microscopic level without invasive procedures. The significance of this lies in the fact that the DHDDS enzyme normally facilitates the synthesis of dolichol, a crucial lipid anchor for N-linked glycosylation. This post-translational modification is essential for the proper folding and function of innumerable glycoproteins across neural tissues.

The study, presented by Dr. Irena Muffels at the European Society of Human Genetics annual meeting, revealed that mutant DHDDS leads to a profound reduction in dolichol production in the mini-brains. This deficiency disrupts glycan assembly—complex sugar structures attached to proteins—thereby compromising the functional integrity of proteins pivotal for brain homeostasis. An intriguing and pathologically relevant secondary effect was uncovered: excessive accumulation of cholesterol within astrocytes. As central nervous system glial cells tasked with metabolic and neuroprotective roles, astrocytes overloaded with cholesterol experience mitochondrial dysfunction, inviting a cascade of energy deficits that plausibly drive the relentless clinical progression observed in affected children.

Confronted with this mechanistic insight, the researchers pursued a novel therapeutic angle by screening a library of FDA-approved vitamins and drugs in collaboration with Perlara Biotech. Their breakthrough came in identifying nicotinamide mononucleotide (NMN), a naturally occurring metabolite of vitamin B3, as capable of rescuing a yeast model deficient in functional DHDDS. Subsequent validation in patient-derived mini-brains showcased remarkable improvements in cellular biomarkers and functional readouts of neurodegeneration.

These improvements translated into observable clinical benefits. Intriguingly, some families began administering NMN supplements prior to the completion of experimental trials and reported reductions in tremor severity, increased energy levels, and improved motor control within weeks. Dr. Muffels recounted these real-world clinical anecdotes with cautious optimism, emphasizing the importance of rigorous testing yet acknowledging the early signs of efficacy in this otherwise untreatable disease.

NMN is not a novel compound in the therapeutic landscape. Previous studies documented its capacity to enhance mitochondrial function in muscle cells from patients with mitochondrial diseases and to alleviate symptom progression in Parkinson’s disease cohorts. NMN’s ability to boost cellular NAD+ levels—an essential coenzyme in redox reactions and energy metabolism—explains its versatile benefits across diseases characterized by mitochondrial compromise. These properties make NMN an attractive candidate not only for DHDDS-related disorders but potentially other genetic metabolic diseases compromising brain energy homeostasis.

Encouraged by these findings, the team initiated a formal international clinical trial, supported by CDG UK, aiming to assess the long-term impact of NMN supplementation in DHDDS patients. This longitudinal study will monitor twelve patients over a year, with standardized evaluations every three months. The global nature of the trial underscores both the rarity of the disease and the collaborative resolve necessary to tackle it, leveraging networks between families, clinicians, researchers, and charities.

The creation of mini-brains from patient-derived induced pluripotent stem cells proved instrumental in this endeavor. These organoids contain diverse neural populations, including neurons and astrocytes, providing a physiologically relevant platform to dissect disease pathology and rapidly test therapeutics. Observations of progressive structural degeneration, mitochondrial impairment, and protein glycosylation deficits within the mini-brains aligned closely with patient phenotypes, validating the model’s translational utility.

Furthermore, this story epitomizes how patient advocacy can accelerate scientific discovery. Driven by desperation and hope, parents bypassed inertia in rare disease research to champion this innovative approach. Such grassroots initiatives are crucial in opening doors for pharmaceutical engagement, often hindered by the economic challenges of developing therapies for ultra-rare disorders.

Professor Alexandre Reymond, chair of the conference and an expert uninvolved with the study, hailed the research as a paradigm for harnessing rapid genetic diagnosis to catalyze new treatments for rare diseases. He highlighted the exceptional synergy of families, academia, and grassroots charities in overcoming traditional hurdles to drug development, delivering a potentially affordable and safe treatment option that could transform lives.

While these advances mark an exciting dawn, challenges remain. Determining the optimal NMN dosing, long-term safety profiles, and mechanistic nuances across diverse patient genotypes warrants further study. Nonetheless, this work paves the way for novel precision medicine approaches that transcend symptom management, aiming instead to arrest underlying pathological mechanisms at the molecular level.

In conclusion, the integration of cutting-edge stem cell technology, meticulous biochemical elucidation, and innovative therapeutics has revitalized hope for children afflicted with DHDDS-related neurodegenerative disease. As research progresses and clinical trials yield definitive data, NMN supplementation may soon shift from experimental to standard care, offering a lifeline to families who previously faced an inexorable decline. This landmark study underscores the transformative potential of merging patient-derived models with metabolic therapies to rewrite the trajectory of rare genetic disorders affecting the brain.

Subject of Research:
Neurodegenerative disease caused by DHDDS gene mutations and therapeutic potential of nicotinamide mononucleotide (NMN).

Article Title:
Mini-Brain Models Unlock Vitamin B3 Therapy for Rare DHDDS Neurodegeneration

News Publication Date:
Not specified; presented at the annual European Society of Human Genetics conference.

Web References:
Not provided in the original content.

References:
Not provided in the original content.

Image Credits:
Not provided in the original content.

Keywords:
DHDDS gene, neurodegeneration, mini-brain organoids, nicotinamide mononucleotide, vitamin B3, congenital neurodegenerative diseases, dolichol deficiency, glycosylation defects, cholesterol accumulation, mitochondrial dysfunction, rare genetic disorders, patient-derived models

Central to this breakthrough is the application of an innovative therapeutic agent dubbed “dancing molecules,” a supramolecular technology developed under the auspices of senior author Samuel I. Stupp. Unlike conventional static molecular drugs, these dynamic molecules exhibit rapid motion within their nanofiber scaffold, mimicking the natural kinetics of cellular receptors and thereby potentiating cell signaling crucial for regeneration. When administered to injured organoids, the therapy markedly stimulated neurite outgrowth, the slender projections of neurons integral to reestablishing functional neural circuits post-injury. Equally notable was the attenuation of glial scar density, a formidable barrier in spinal injury recovery, underscoring the therapeutic’s multifaceted efficacy.

Organoids, derived from induced pluripotent stem cells, serve as simplified yet remarkably faithful replicas of human tissue. These three-dimensional constructs preserve the intricate cellular heterogeneity and microenvironment of native organs, making them exceptional models for human disease study and drug efficacy testing. While organoid technologies have been applied across various domains, Northwestern’s spinal cord model distinguishes itself by integrating microglia, the central nervous system’s resident immune cells, thereby authentically recapitulating the inflammatory milieu that follows traumatic injury. This incorporation advances the organoid’s physiological relevance significantly beyond prior iterations.

In their experimental design, the investigators induced two distinct injury paradigms within the organoids—laceration and contusion—mirroring clinical scenarios that arise from surgical trauma or blunt force impacts, respectively. These controlled insults reproduced cellular demise and scar formation observed in actual spinal cord injuries, validating the organoid’s utility as a precise injury model. Upon treatment with dancing molecules, these injured tissues exhibited robust regeneration marked by the resurgence of neurite networks and reorganization of neuron architecture, indicative of functional neural recovery potential.

The “dancing molecules” technology itself represents a paradigm shift in molecular therapeutics. Formed from supramolecular peptide assemblies exceeding 100,000 molecules, these compounds leverage collective molecular motion to engage cell surface receptors actively. This dynamic interaction contrasts with static ligand-receptor binding, accounting for enhanced signal transduction and subsequent tissue repair. Injected as a liquid, the preparation swiftly solidifies into a nanofiber matrix resembling the extracellular matrix of spinal tissue, providing both mechanical support and bioactive signaling conducive to neuronal regeneration.

Evidence from prior animal studies corroborates the therapeutic’s promise; a single administration within 24 hours post-injury enabled paralyzed mice to regain ambulation within four weeks. These findings underscore a potent link between molecular mobility and therapeutic efficacy, with formulations engineered for heightened motion outperforming slower, less dynamic counterparts. The human organoid experiments further solidify this relationship, as dynamic molecules were uniquely effective in promoting neurite extension, highlighting the importance of molecular kinetics in regenerative medicine.

Samuel I. Stupp and his team’s spinal cord organoid model not only offers a cutting-edge platform for therapeutic evaluation but also opens avenues for personalized medicine. By utilizing a patient’s own stem cells to grow organoids, it may become feasible to tailor injury models and treatments that minimize immune rejection risks. Moreover, the group plans to innovate models that mimic chronic spinal cord injuries, which are characterized by entrenched scar tissue resistant to repair, thereby addressing a critical unmet need in neuroregeneration research.

The successful simulation of inflammatory responses within the organoid is of particular significance. Microglia-mediated inflammation plays a dual role in injury, contributing to both neurotoxicity and repair. By incorporating microglial populations, the organoid model allows nuanced exploration of this balance, facilitating the design of interventions that modulate immune activity to favor regeneration while limiting secondary neuronal damage. This adds a layer of fidelity that could drastically improve the predictive validity of preclinical therapeutic screens.

Neurological disorders such as paralysis following spinal trauma have long baffled clinicians due to the complex interplay of molecular and cellular elements governing injury and repair. With this advanced human model, researchers can now dissect these processes with unprecedented clarity. Observations of astrocyte morphology distinguishing normal from scar-forming phenotypes, alongside measurements of chondroitin sulfate proteoglycans—key molecules implicated in inhibiting axonal regrowth—offer mechanistic insights essential for developing targeted interventions.

The implication of dancing molecules extends beyond spinal cord injury repair. This supramolecular therapeutic approach paves the way for broader applications across regenerative medicine, where molecular motion dynamics can be harnessed to optimize cell receptor engagement and signaling. Notably, Stupp’s lab’s previous ventures into similar technologies have influenced treatment regimes for metabolic diseases, demonstrating the versatility and transformative potential of motion-based molecular therapeutics.

This convergence of organoid technology and dynamic supramolecular therapeutics exemplifies a new frontier in biomedical engineering, facilitating not only mechanistic research but also translational medicine. By bridging the gap between traditional animal models and human clinical trials, these innovations accelerate the path toward effective therapies, holding promise to dramatically improve quality of life for patients enduring paralysis and sensory deficits post-spinal cord injury.

The study titled “Injury and therapy in the human spinal cord organoid” was supported by Northwestern University’s Center for Regenerative Nanomedicine and philanthropic contributions from the John Potocsnak Family. The full research further details the sophisticated design and compelling results of this organoid-based regenerative platform, cementing its role as a pivotal tool in the evolving landscape of neurological injury treatment.

Subject of Research: Lab-produced tissue samples

Article Title: Injury and therapy in a human spinal cord organoid

News Publication Date: 11-Feb-2026

Web References:

• https://dx.doi.org/10.1038/s41551-025-01606-2
• https://news.northwestern.edu/stories/2021/11/dancing-molecules-successfully-repair-severe-spinal-cord-injuries/

References:

• Samuel I. Stupp et al., “Injury and therapy in the human spinal cord organoid,” Nature Biomedical Engineering, 2026.

Image Credits: Samuel I. Stupp/Northwestern University

Keywords: Spinal cord injuries, Spinal cord, Traumatic injury, Contusions, Puncture wounds, Spinal injuries, Paralysis, Organoids, Organ cultures, Medical treatments, Nerve growth, Neurite outgrowth, Neurites

Heart failure, especially when caused by the aftermath of a myocardial infarction, presents an immense clinical challenge since the adult human heart has limited regenerative capacity. When cardiac cells suffer oxygen deprivation during a heart attack, the resultant cell death triggers scar formation rather than regeneration, weakening the heart’s pumping efficiency. Restoring lost contractile tissue has long been an elusive goal, yet researchers have now engineered a method that may bring this vision closer to reality.

The heart tissue patch at the core of this breakthrough is crafted using induced pluripotent stem cells (iPSCs), which are adult cells reprogrammed to regain their developmental versatility. These iPSCs can then be coaxed to differentiate into various cardiac lineages, including muscle cells, vascular endothelial cells, and fibroblasts. By combining these cell types in a specialized scaffold, the team has recreated a living, functional piece of heart muscle capable of integration with the host organ.

A key innovation is the substrate used to house these cells; a flexible, paper-thin patch composed of nano- and microfibers coated with gelatin provides a biodegradable scaffold that mimics the extracellular matrix. This hybrid scaffold not only facilitates cell adhesion and survival but also can be folded and loaded into slender delivery devices. Coupled with the application of bioactive molecules like fibroblast growth factor 1 and the Wnt signaling modulator CHIR99021, the engineered tissue encourages vascularization and cell viability post-transplantation.

Underscoring the technique’s clinical potential is its minimally invasive delivery. Instead of subjecting patients to the risks and extended recovery times associated with open-heart surgery, the patch is introduced through a small chest incision using a slender tube. Upon reaching the heart, the patch unfolds and naturally adheres to the organ’s surface with the help of a biocompatible surgical adhesive, obviating the need for sutures and minimizing trauma to the surrounding tissue.

Preclinical trials employing rodent models of chronic myocardial infarction have demonstrated compelling outcomes. Animals that received the stem cell patch displayed significant improvements in cardiac contractility, reduced scarring zones, increased formation of new blood vessels, and dampened inflammatory responses compared to controls. These effects collectively translated into enhanced cardiac function, suggesting that the engineered tissue not only interfaces with the damaged myocardium but actively promotes its regeneration.

The implications of this research align closely with the mission of the Mayo Clinic’s Genesis Initiative, which seeks to accelerate innovations in regenerative medicine. By marrying stem cell biology with bioengineering and minimally invasive delivery strategies, Dr. Wuqiang Zhu and his collaborators envision a future where patients suffering from heart failure can be treated with personalized, cell-based therapies that restore native heart function without the complications of donor shortages or extensive surgery.

Currently, heart transplantation remains a gold-standard for end-stage heart failure but is severely limited by donor availability and long wait times, often resulting in high mortality rates among candidates. Mechanical support devices provide interim solutions but carry risks of infection, thrombosis, and reduced quality of life. The engineered tissue patch could represent a third paradigm, where patients receive implants derived from their own cells via a safe and accessible procedure, potentially transforming morbidity and mortality outcomes on a global scale.

While the promise is extraordinary, translation to human patients demands rigorous testing. The Mayo Clinic research team is preparing to advance from small animal studies to larger preclinical models to evaluate long-term safety, dosing, and functional integration. Dr. Zhu estimates that clinical trials could commence within five years, heralding a new era in cardiac regenerative therapy.

This breakthrough exemplifies the synergy between bioengineering, stem cell science, and translational medicine. The ability to create a living, beating piece of heart tissue in the lab and deliver it through a minimally invasive technique addresses longstanding barriers and paves the way for personalized regenerative solutions in cardiology. As the population ages and heart failure incidence grows worldwide, such innovations are not merely desirable—they are imperative.

The scientific community and patients alike await further developments with anticipation. If successful, this method could salvage hearts once considered irreparably damaged, reduce reliance on organ transplantation, and improve the quality and longevity of life for millions. By offering a toolkit to heal the heart from within, the Mayo Clinic team’s work sets a new standard for what regenerative medicine can achieve.

Subject of Research: Regeneration of damaged heart tissue using stem cell-derived engineered cardiac patches delivered through minimally invasive procedures.

Article Title: Minimally invasive delivery of engineered heart tissues restores cardiac function in rats with chronic myocardial infarction

News Publication Date: 30-Aug-2025

Web References:
– Mayo Clinic: https://www.mayoclinic.org/
– Mayo Clinic Arizona: https://www.mayoclinic.org/patient-visitor-guide/arizona
– Heart attack information: https://www.mayoclinic.org/diseases-conditions/heart-attack/symptoms-causes/syc-20373106
– Heart failure information: https://www.mayoclinic.org/diseases-conditions/heart-failure/symptoms-causes/syc-20373142
– Heart transplant facts: https://www.mayoclinic.org/tests-procedures/heart-transplant/about/pac-20384750
– Mayo Clinic News Network: https://newsnetwork.mayoclinic.org/

References:
Minimally invasive delivery of engineered heart tissues restores cardiac function in rats with chronic myocardial infarction, Acta Biomaterialia, 30 August 2025

Keywords:
Stem cells, heart regeneration, cardiac tissue engineering, myocardial infarction, minimally invasive surgery, induced pluripotent stem cells, bioengineered cardiac patch, cardiac function restoration, regenerative medicine, Mayo Clinic, biotechnology, tissue scaffold